191 related articles for article (PubMed ID: 36979944)
21. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722
[TBL] [Abstract][Full Text] [Related]
22. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
[TBL] [Abstract][Full Text] [Related]
23. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
Tanaka Y; Bae SC; Bass D; Curtis P; Chu M; DeRose K; Ji B; Kurrasch R; Lowe J; Meizlik P; Roth DA
RMD Open; 2021 Jul; 7(2):. PubMed ID: 34215703
[TBL] [Abstract][Full Text] [Related]
24. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
[TBL] [Abstract][Full Text] [Related]
25. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies.
Collins CE; Cortes-Hernández J; Garcia MA; von Kempis J; Schwarting A; Touma Z; Kurtinecz M; Gairy K
Rheumatol Ther; 2020 Dec; 7(4):949-965. PubMed ID: 33206344
[TBL] [Abstract][Full Text] [Related]
26. Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review.
Huang SP; Snedecor SJ; Nanji S; Lloyd E; Bell CF
Rheumatol Ther; 2022 Aug; 9(4):975-991. PubMed ID: 35596922
[TBL] [Abstract][Full Text] [Related]
27. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
28. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
Wang L; Liang X; Cao Z; Wang D; Luo Y; Feng Y; Luo C; Zhi S; Huang Y; Fan Z; Wang C; Liu H; Liu J; Zhang T; Cheng Q; Xie X; Shuai L; Rong Z; Zeng P; Yu H; Lu M; Sun L; Yang S; Zhao D; Zhang W; Wu X; Li Q; Wang Y; Zhang Q; Yang J; Li X; Song H; Tang X
Rheumatology (Oxford); 2024 May; 63(5):1437-1446. PubMed ID: 37606970
[TBL] [Abstract][Full Text] [Related]
30. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
[TBL] [Abstract][Full Text] [Related]
31. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
32. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
33. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Zheng J; Gu J; Su Y; Li Y; Li X; Xiong C; Cao H; Quasny H; Chu M; Curtis P; DeRose K; Kurrasch R; Meizlik P; Roth DA; Zhang F
Mod Rheumatol; 2023 Jul; 33(4):751-757. PubMed ID: 36208293
[TBL] [Abstract][Full Text] [Related]
35. Real-World Effectiveness of Belimumab in Patients with Active Lupus.
Sumichika Y; Yoshida S; Suzuki E; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137696
[TBL] [Abstract][Full Text] [Related]
36. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
37. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
38. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
[TBL] [Abstract][Full Text] [Related]
39. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
40. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]